The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state

Hellenic Journal of Nuclear Medicine

Volumn 12, Issue 3, 2009, Pages

  Zissimopoulos, Athanasios ^a   Bantis, Athanasios ^a   Sountoulides, Petras ^a   Giannakopoulos, Stelios ^a   Kalaitzis, Christos ^a   Agelonidou, Eleni ^a   Touloupidis, Stavros ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Bone metastases; Chromogranin A PSA; Prostate cancer

Indexed keywords

ANDROGEN; ANTIANDROGEN; CHROMOGRANIN A; GONADORELIN AGONIST; MEDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BLOOD DONOR; BONE METASTASIS; BONE SCINTISCANNING; CANCER PATIENT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; GLEASON SCORE; HORMONE RESISTANCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROTEIN BLOOD LEVEL;

ADULT; AGED; ANDROGEN ANTAGONISTS; CHROMOGRANIN A; DRUG RESISTANCE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 72249108923     PISSN: 11081430     EISSN: 17905427     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Bantis A, Vasiliou O. Prostate cancer incidence, mortality, total and free prostate specific antigen. Hell J Nucl Med 2009; 12: 106-109.
2. Eble J, Sauter G, Epstein J et al. World Health OrganizationClassification of Tumours. Pathology and Genetics of Tumours of the Urinary system and Male Genital Organs. IARC Publications, Lyon, 2004.
3. Berruti A, Mosca A, Tucci M. Independent prognostic role of circulatingchromogranin A in prostate cancer patients with hormone-refractory disease. Endocrine-Related Cancer 2005; 12: 109-117. (Pubitemid 40477092)
4. Bantis A, Zissimopoulos A, Athanasiadou P et al. Serum testosterone, dihydrotestosterone, luteinizing hormone and follicle-stimulating hormone versus prostate specific antigen in patients with localized prostate adenocarcinoma who underwent radical prostatectomy. Radioimmunoassays measurements. Hell J Nucl Med 2007; 10: 56-61. (Pubitemid 46692253)
5. Stoll BA. Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbho S. Eds. Bone metastases monitoring and treatment. New York: Raven Press. 1983, pp.1-4.
6. Bantis A, Zissimopoulos A, Kalaitzis C. Four prognostic indices in advanced prostate cancer patients, under palliative androgen deprivation treatment. Hell J Nucl Med 2008; 11: 21-25. (Pubitemid 351649753)
7. Jongsma J, Oomen M, Noordzij M et al. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002; 50: 203-215. (Pubitemid 34184659)
8. Yamamoto S, Maruyama T, Kondoh N et al. Diagnostic efficacy of free to total ratio of prostate-specific antigen and prostate-specific antigen velocity, singly and in combination, in detecting prostate cancer in patients with total serum prostate-specific antigen between 4 and 10ng/ml. Int Urol Nephrol 2008; 40: 85-89.
9. Miotto AJr, Srougi M, Brito GA et al. Value of various PSA parameters for diagnosing prostate cancer in men with normal digital rectal examination. Int Braz J Urol 2004; 30: 109-113. (Pubitemid 38714202)
10. Chan DW, Sokoll U et al. Prostate-specific antigen: update 1997. J Int Fed Clin Chem 1997; 9: 120-125.
11. Grammaticos P. Diagnostic and prognostic importance of prostate specific antigen in prostate carcinoma. Hell J Nucl Med 2004; 7: 146. (Pubitemid 40185990)
12. Oesterling J, Martin S, Bergstralh E, Lowe F. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60. (Pubitemid 23006523)
13. Berruti A, Dogliotti L, Mosca A et al. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma. Annals of Oncology 2001; 12 (Suppl 2) S153-S157. (Pubitemid 33069706)
14. Soloway M, Hardeman S, Hickey D et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer 1988; 61: 195-202. (Pubitemid 18023133)
15. Stridsberg M. Measurements of chromogranins and chromograninrelated peptides by immunological methods. Adv Exp Med Biol 2000; 482: 19-27. (Pubitemid 32174541)
16. Wu TJ, Astill ME, Liu GH, Stephenson RA. Serum chromogranin A: Early detection of hormonal resistance in prostate cancer patients. J Clin Lab Analysis 1998; 12: 20-25.
17. Abrahamsson PA. Neuroendocrine cells in tumour growth of the prostate. Endocr Relat Cancer 1999; 6: 503-519.
18. Evans A, Humphrey P, Belani J et al. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006; 30: 684-693. (Pubitemid 44264993)
19. Krijnen J, Bogdanowicz J, Seldenrijk C et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997; 158: 171-174. (Pubitemid 27251617)
20. Sasaki T, Komiya A, Suzuki H. Changes in Chromogranin A Serum Levels During Endocrine Therapy in Metastatic Prostate Cancer Patients. Eur Urol 2005; 48: 224-229. (Pubitemid 40957093)
21. Sciarra A and Di Silverio F. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Urology 2004; 63: 523-527.
22. Sciarra A, Monti S, Gentile V et al. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate 2003; 55: 168-179. (Pubitemid 36532395)
23. Mc William L, Mansosn C, George N et al. Neuroendocrine differentiation and prognosis in prostatic adenocarcinoma. Br J Urol 1997; 80: 287-290. (Pubitemid 28318898)
24. Isshiki S, Akakura K, Komiya A et al. Chromogranin A concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer. J Urol 2002; 167: 512-515. (Pubitemid 34074517)
25. Kalkner K, Acosta S, Thorsson O et al. Octreotide scintigraphy and Chromogranin A do not predict clinical response in patients with octreotide acetate-treated hormonerefractory prostate cancer. Prostate Cancer Prostatic Dis 2006; 9: 92-98. (Pubitemid 43378876)